News | October 30, 2023
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Orgovyx is the first and only oral GnRH receptor antagonist approved for advanced prostate cancer in Canada
New Molecular biology lab launched, AIIA increased its work scope in form of MoUs
Investment is additive to KKR’s existing health care growth strategy
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
ASMD is highly variable and the age of onset, specific symptoms and severity of the disorder can vary dramatically from one person to another
Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months
Pant delivers keynote address at National Conclave on “Augmented Zoonotic Diseases Surveillance at Human – Wildlife Interface”
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Subscribe To Our Newsletter & Stay Updated
